Genor Biopharma Holdings (6998.HK) Q4 2025 Earnings Report

Genor Biopharma delivered a standout Q4 2025, underscoring the strength of its diversified oncology and autoimmune portfolio. Revenue of CNY 2.414 billion, gross profit of CNY 1.325 billion and a gross margin of 54.96% reflect a favorable product mix and continued demand for Genor’s clinical-stage assets and biosimilar strategies. The quarter produced an EBITDA of CNY 770.3 million and net income of CNY 446.0 million, with basic and diluted EPS of CNY 0.34 and CNY 0.33, respectively, indicating meaningful profitability on a quarterly basis.

The results show pronounced YoY and QoQ growth, with reported YoY revenue up roughly 2,418% and QoQ revenue up about 7,387% according to the provided normalized metrics, driven by improved sales mix and milestone-related recognition in a high-growth biotechnology landscape. Operating margins rose to ~19.1%, and net margins approached 18.5%, signaling a healthy scale-up in profitability alongside pipeline execution.

Looking ahead, Genor’s forward-looking trajectory hinges on the progression and potential monetization of key candidates, including GB226 (PD-1 mAb), GB491 (lerociclib), GB492 (STING agonist), and broader GB242 biosimilar opportunities. While explicit management guidance for 2026 is not disclosed in the data, the pipeline milestones and China-market expansion plans are potential catalysts. Investors should monitor clinical readouts, regulatory developments, and potential collaborations or licensing deals that could materially alter revenue trajectories and capital efficiency.